ClinicalTrials.gg
RecruitingNCT05715814CANARYUpdated May 1, 2026

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

A Phase 3 interventional study of Empagliflozin 25 MG in Peritoneal Dialysis Complication, End Stage Kidney Disease and Sodium-glucose Co-transporter-2 Inhibitors, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University Health Network, Toronto · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.

Planned enrollment
93rd of 110
20 · median 79
Started
2024
with 7 others
Phase 3
23 of 134
2 open now
Primary completion
2027-05
later than 14 of 27 live
Registered
117th of 134
by date
Lead sponsor
8 of 134
University Health Network, Toronto

Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 93rd largest by planned enrollment of the 110 interventional ones that give a count, is one of 8 that started in 2024, is one of 23 in phase 3, reaches primary completion later than 14 of the 27 other live ones, and was the 117th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Kidney Failure, Chronic with a site in Canada, or all of them as a file.
02

Study summary

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Read the detailed description

The importance of RKF on the survival of patients on PD has been demonstrated in several observational studies. Despite this, there are limited pharmacological interventions available to slow the loss of RKF in these patients. There is an unmet need for novel cardiovascular and kidney protective strategies for patients on renal replacement therapies, including PD.

SGLT2 inhibitors have been shown to have both cardiovascular and kidney protective effects in individuals with kidney disease, with and without diabetes. These benefits have been attributed to diverse mechanisms and kidney benefits have been largely attributed to reductions in intraglomerular pressure at the single nephron level, reversibly lowering GFR in the short-term with long-term benefits. However, the beneficial effects of SGLT2 inhibitors have never been studied in patients on dialysis.

The CANARY study will provide insight into the safety and mechanisms of SGLT2 inhibitors in individuals on dialysis with RKF, with and without type 2 diabetes, over a period of 2 weeks. Demonstrating that protective mechanisms associated with SGLT2 inhibitors are intact in patients on PD with RKF would provide a strong rationale for a larger clinical trial to explore the use of these novel drugs in this unique clinical application. Additionally, our proposed study would provide timely mechanistic data to inform clinical decisions in the context of other large clinical trials such as EMPA-KIDNEY. These findings would help physicians make decisions on leaving patients on SGLT2 inhibitors even beyond end-stage kidney disease.

03

Conditions studied

  • Peritoneal Dialysis Complication
  • End Stage Kidney Disease
  • Sodium-glucose Co-transporter-2 Inhibitors
  • Kidney Dysfunction
  • Residual Kidney Function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written .
  • Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured of 2 ml/min/1.73m2, as measured at least once in the last 3 months.
  • Stable PD prescription, as determined by investigators.
  • Stable dose of RAAS blockade if on a medication within this class for the last 30 days.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes.
  • Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.
  • PD peritonitis within 30 days of screening.
  • History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.
  • Planned surgery/procedures or radiologic investigations requiring contrast during the trial.
  • Pregnant, planning to become pregnant, or nursing an infant during the study period
  • History of any DKA event
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening.
  • Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.
  • Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement.
  • Use of SGLT2 inhibitor within 30 days prior to screening.
  • Intake of an drug in another trial within 30 days prior to screening.
  • Patient not able to understand and comply with study requirements, based on Investigator's judgment.
  • Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. patients, active , patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and/or hepatorenal syndrome, severe hepatic impairments etc.).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Empagliflozin

    Drug: Empagliflozin 25 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Change in measured GFR

    GFR will be determined from the average of creatinine and urea clearance from a 24-hour urine collection.

    Time frame: Before and 2 weeks after initiation of empagliflozin.

Secondary outcomes

  1. Rebound in GFR after Cessation of Therapy

    A GFR measurement will be performed 2 weeks after cessation of empagliflozin, with the aim of capturing the reversible "rebound" in GFR after cessation of therapy.

    Time frame: 2 weeks

  2. Change in ultrafiltration volume

    Time frame: 2 weeks

  3. Change in fraction of glucose remaining in the dialysate

    Time frame: 2 weeks

  4. Change in dialysate/plasma creatinine

    Time frame: 2 weeks

  5. Change in dialysate/plasma urea

    Time frame: 2 weeks

  6. Change in sodium dialysate concentration

    Time frame: 2 weeks

  7. Change in glycated hemoglobin (HbA1c)

    Time frame: 2 weeks

  8. Change in systolic and diastolic blood pressure

    Time frame: 2 weeks

  9. Change in body weight

    Time frame: 2 weeks

  10. Change in body composition (percent body mass, body fat, and muscle mass)

    Bioimpedence measurements will be taken to study the effects of intervention on body composition.

    Time frame: 2 weeks

  11. Change in fractional urine excretion of sodium

    Urinary analysis will be performed to quantify the amount of sodium excretion.

    Time frame: 2 weeks

  12. Change in fractional urine excretion of glucose

    Urinary analysis will be performed to quantify the amount of glucose excretion.

    Time frame: 2 weeks

  13. Change in eGFRβ2-microglobulin

    Blood sample analysis to assess middle molecule clearance.

    Time frame: 2 weeks

  14. Change in degree of albuminuria

    Urinary analysis will be performed to determine if there has been any change in the severity of albuminuria

    Time frame: 2 weeks

  15. Change in BNP (NT-proB-type Natriuretic Peptide)

    Time frame: 2 weeks

  16. Change in markers of neurohumoral activation, erythropoiesis, and inflammation.

    Time frame: 2 weeks

  17. The safety of empaglifllozin use in PD patients with RKF with regard to anuria (<100cc/day), volume depletion, diabetic ketoacidosis, genito-urinary infections, PD peritonitis and death will be evaluated.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.

Of 66 phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 48. This study's planned 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2023
First posted
Feb 8, 2023
StartActual
Sep 1, 2024
Primary completionEst.
May 1, 2027
CompletionEst.
Dec 1, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05715814
Responsible party
Sunita Singh, MD, MSc, FRCPC (Clinician Scientist, University Health Network, Toronto) — Principal investigator
First posted
Feb 8, 2023
Start date
Sep 1, 2024
Primary completion
May 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Vesta Lai
Contact
vesta.lai@uhn.ca
416-340-4800 ext. 8508
Sunita KS Singh, MD MSc FRCPC
principal investigator · University Health Network, Toronto General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion